

REMARKS

Procedural posture and status of the claims

This amendment and response accompanies a Request for Continued Examination (RCE). Applicants respectfully request that the finality of the prior office action be withdrawn and the current paper entered and considered pursuant to 37 C.F.R. § 1.114. Applicants file concurrently herewith a Supplemental IDS and respectfully request that it too be entered and considered.

Claims 27 - 36, 38 - 42 and 52 are pending and have been rejected.

Claims 27, 35, 36, 41, and 52 are amended herein for the reasons advanced below. No new matter has been added.

Claims 27 - 36, 38 - 42 and 52 are thus pending and presented for further examination.

Rejections under 35 U.S.C. §101

Claims 27, 28, 32 - 40 and 52 have been rejected under 35 U.S.C. § 101 as reading on nonstatutory subject matter.

Applicants herein amend independent claims 27, 35, and 52 in accordance with the Examiner's suggestion, inserting the modifier "isolated" before "peptide", and respectfully submit that this amendment is fully remedial and that the rejection, having been obviated, should be withdrawn.

Rejections under 35 U.S.C. §112, ¶ 1, scope of enablement

Acknowledging that the specification enables "a method of inhibiting DM2 protein binding to p53 in vitro," the Examiner maintains that the specification nonetheless "does not reasonably provide enablement for a method of inhibiting the binding of DM2 and p53 *in vivo*. . . ." Office action, p. 2.

Applicants respectfully traverse the rejection, in part for the reasons already made of record. However, solely to expedite prosecution, and without prejudice to prosecution of claims of the original scope in one or more continuation applications, applicants herein amend claim 41 to recite that DM2 is contacted *in vitro* with the claimed peptide, and respectfully submit that the rejection has been obviated and should be withdrawn.

Rejections under 35 U.S.C. § 102

Claims 27, 28, 33, 35, 36, 38 - 42 and 52 have been rejected under 35 U.S.C. § 102(a) as anticipated by Böttger *et al.*, *Oncogene* 13:2141 - 2147 (1996) ("Böttger"). Claims 29 - 32 and 34 are free of this rejection.

The publication of Böttger in November 1996 intervenes between applicant's first and second priority filings, GB 9614197.3 (filed July 5, 1996) and GB 9707041.1 (filed April 7, 1997), respectively. Although Böttger is a report by the inventors themselves of at least a portion of the results set forth in the instant application, its authorship is not fully congruent with the current inventorship entity, making the reference available under § 102(a) as against claims that are entitled to a priority date no earlier than the April 1997 second priority date.

Applicants herein amend independent claims 27, 35, 36, and 41 to limit peptide residue R₂ to any one of arginine (R), histidine (H), or aspartic acid (D). As so amended, these claims, and the claims dependent therefrom, are fully described in the specification of applicants' first priority application.¹

¹ As a courtesy, applicants provide herewith a true and correct copy of applicants' July 5, 1996 priority GB application, no. 9614197.3, already of record in this § 371 national phase application. Support for the claims now pending may be found throughout this first priority specification, and particularly in the claims as originally filed, notably claims 2, 4, and 6, and in the sequences of the peptides listed pages 15 - 18, each of which has one of arginine (R), histidine (H), or aspartic acid (D) at position R₂.

Applicants respectfully submit that the claims as amended herein validly claim priority under 35 U.S.C. § 119(a) to applicants' first priority application, and were thus constructively reduced to practice prior to the effective date of the Böttger reference. Applicants respectfully submit that Böttger, having been so antedated, is no longer available as a reference as against the claims now pending, and that the rejection should be withdrawn.

Rejections under 35 U.S.C. §103

The Examiner rejects claims 27 - 32 over Böttger, further in view of Dower *et al.*, U.S. Pat. No. 6,121,238 ("Dower").


Having perfected claim to the benefit of applicants' first priority application, 35 U.S.C. § 119(a), applicants respectfully submit that Böttger is no longer available as a reference under 35 U.S.C. § 102(a). With the primary reference of the combination removed, the Examiner's *prima facie* case of obviousness has been vitiated and applicants are entitled, without more, to withdrawal of the rejection and allowance of their claims, *In re Oetiker*, 977 F.2d 1443 (Fed. Cir. 1992).

CONCLUSION

Applicants respectfully submit that the present application is in condition for allowance. If the Examiner believes, however, that any matters remain outstanding before passing the case to issue, applicants respectfully request that she call the undersigned at (650) 324-7014 to arrange a telephonic interview.

Respectfully submitted,

Dated: 2 MARCH 2005



Daniel M. Becker
Reg. No. 38,376

for: Ginger R. Dreger
Reg. No. 33,055
Attorney of Record

HELLER EHRMAN WHITE & McAULIFFE, LLP
Customer No. 25213
275 Middlefield Road
Menlo Park, CA 94025
Telephone: (650) 324-7000
Facsimile: (650) 324-0638

Patent JUL '96 11:06 CG PATENTS DEPT MA 01625 888555

Patent Act 1977
s. 16)Patent
Office

9614197.3

Request for grant of a patent*(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form.)*

The Patent Office

- 5 JUL 1996

Cardiff Road
Newport
Gwent NP9 1RH

1. Reference

4-20937/P1/B1171

2. Patent application number

*(The Patent Office will fill in this part)*3. Full name, address and postcode of the or of each applicant *(underline all surnames)*CIBA-GEIGY AG
141 KLYBECKSTRASSE
CH 4002, BASLE
SWITZERLANDUniversity of Dundee
Perth Road
Dundee
DD1 4HN
ScotlandPatents ADP number *(if you know it)*

289256001

If the applicant is a corporate body, give the country/state of its incorporation

SWITZERLAND

4. Title of the invention

Inhibitors of the interaction between P53 and MDM2

5. Name of your agent *(if you have one)*"Address for service" in the United Kingdom to which all correspondence should be sent *(including the postcode)*Mr B.A. Marsh
CIBA-GEIGY PLC
PATENT DEPARTMENT
HULLEY ROAD
MACCLESFIELD
SK10 2NXNOVARTIS UK LIMITED
PATENTS & TRADE MARKS
CENTRAL RESEARCH
HULLEY ROAD
MACCLESFIELD
CHESHIRE
SK10 2NXPatents ADP number *(if you know it)*

5898671002

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and *(if you know it)* the or each application number

Country

Priority application number
*(if you know it)*Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
*(day / month / year)*8. Is a statement of inventorship and of right to grant of a patent required in support of this request? *(Answer 'Yes' if:*

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

See note (d))

Yes

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form -

Description 30

Claim(s) 2

Abstract 1

Drawing(s) -

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

Date

B. A. Marsh

5.7.96

12. Name and daytime telephone number of person to contact in the United Kingdom

B. A. Marsh

01625 888516

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered "Yes" Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

- 1 -

Inhibitors of the Interaction between P53 and MDM2

The present invention relates to compounds capable of binding to the oncogene protein MDM2, processes for the preparation of such compounds, pharmaceutical preparations comprising such compounds, and uses of said compounds, e.g. in the therapeutic (including prophylactic) treatment of an animal or especially of the human body.

Inactivation of the p53 tumour suppressor is a frequent event in human neoplasia. Such inactivation of p53 may, for example, result from the binding of a cellular oncogene protein, such as MDM2. The protein encoded by the *mdm2* gene, which is also referred to as *hdm2* (human double minute 2) gene in the art, is capable of forming a complex with p53 both *in vitro* and *in vivo* and inhibit p53-mediated transactivation (J. Momand et al., Cell 69, 1237-1245 (1992)). Formation of this complex favors nucleoplasmic transformation because the complexed p53 essentially loses its tumor suppressor activity. MDM2 is overproduced in about 30 % of the human sarcomas and contributes to an oncogenic phenotype. Compounds preventing or decreasing the binding of MDM2 to p53 alleviate the sequestration of p53, thus promoting p53 tumor suppressor activity. The MDM2 binding site is localized within the region of p53 represented approximately by amino acids 13 to 31 (PLSQETFSDLWKLLPENNV; single letter code) of mature human p53 protein. Recently, it has been found that peptide fragments of p53 which include the amino acid motif FxxLW wherein F, L, and W represent the single letter codes for amino acids phenylalanine, leucine and tryptophan, respectively, and X may be any amino acid, would be particularly suitable for interfering with the binding between p53 and MDM2 (Picksley et al., Oncogene 9, 2523-2529 (1994)). However, there still is a need for compounds which are potent inhibitors of P53-MDM2 binding, and therefore beneficial in the treatment of p53-related diseases, such as (hyper)proliferative diseases. It is the object of the present invention to fulfill this and other needs.

The present invention is based on the surprising finding that a peptide with the phage consensus amino acid sequence P-X-F-X-D-Y-W-X-X-L, wherein X is any naturally occurring L-amino acid, and P, F, D, W and L represent the L-amino acids of proline (P), phenylalanine (F), aspartic acid (D), tyrosine (Y), tryptophan (W) and leucine (L), respectively, given in the single letter code, is capable of blocking the interaction of MDM2 with p53, as determinable

- 2 -

e.g. in an ELISA assay, and shows a significant increase in specific blocking activity over the wildtype p53 peptide sequence.

As used herein, "mdm" refers to the oncogene and "MDM" refers to the protein obtainable as a result of expression of said gene. Even though in the strict sense "mdm" means "murine double minute gene2", as used herein it also refers to dm2 mutants, particularly interspecies mutants, such as hdm2 (human double minute gene2) in particular.

More specifically, it is the object of the present invention to provide peptides, and derivatives thereof, capable of binding to MDM2, particularly human DM2, and specifically inhibiting or blocking the binding of MDM2 to the p53 protein, particularly human p53, *in vitro* or *in vivo*. Such peptides mimic the MDM2 binding site on p53. The peptides provided herein comprise an amino acid motif (in N- to C-terminal order) of the formula



wherein

R_1 and is a proline (P), leucine (L), glutamic acid (E), cysteine (C) or glutamine (Q), preferably a proline

X stands for one (any) natural amino acid,

R_3 is histidine (H), phenylalanine (F) or preferably tyrosine,

R_4 is phenylalanine (F), glutamine (Q) or preferably leucine (L); and

F and W (as well as the capital letters given in brackets above) are used in accordance with the commonly used single letter code for amino acids and represent phenylalanine and tryptophan, respectively.

As used herein, the term "amino acid(s)" includes the free (charged or uncharged) form, or the monovalent or bivalent radical, the latter also being referred to as "amino acid residue". For example, in a 10mer peptide of formula (I), R_1 and R_4 are monovalent radicals, R_1 having a free amino group and R_4 having a free carboxy group, and X, for example, is a bivalent amino acid radical.

Preferred peptides of the invention comprising the amino acid motif of formula (I) are peptides consisting of no more than fifteen amino acids (15mers), particularly 12mer, 13mer, 14mer or 15mer peptides. In such 11mer to 15mer peptides, natural amino acid residues may be attached to the 10mer motif of formula (I) at the N-terminus, i.e. such additional amino acids precede R_1 , at the C-terminus, i.e. such amino acids follow R_4 , or at both ends. Sequences of exemplary 12mer and 15mer peptides are given e.g. in Example 7 hereinbelow.

- 3 -

As used herein, a natural amino acid is a natural α -amino acid having the L-configuration, such as those normally occurring in natural proteins. Unnatural amino acid refers to an amino acid, which normally does not occur in proteins, e.g. an epimer of a natural α -amino acid having the L-configuration, that is to say an amino acid having the unnatural D-configuration; or a (D,L)-isomeric mixture thereof; or a homologue of such an amino acid, for example a β -amino acid or an α -amino acid wherein the amino acid side chain has been shortened by one or two methylene groups or lengthened to up to 10 carbon atoms, such as an α -amino alkanic acid with 5 up to and including 10 carbon atoms in a linear chain, an unsubstituted or substituted aromatic (α -aryl or α -aryl lower alkyl), for example a substituted phenylalanine or phenylglycine.

By selectively disrupting or preventing p53 from binding to MDM2 through its MDM2 binding site, the peptides of the invention, or derivatives thereof, can significantly decrease or avoid the negative regulatory effects of MDM2 on p53 activity. Therefore, the peptides, or derivatives thereof, of the invention can be used to restore p53 tumour suppressor function, e.g. in the treatment of tumour diseases or viral infections when enhanced activity of p53 is desired or required.

The peptide sequences of the invention show some homology to the sequence on p53 required for MDM2 binding, however, additional homologies are present which are absent from p53.

Preferred peptides of the invention include the following (amino acid sequences are given in single letter code):

M-P-R-F-M-D-Y-W-E-G-L-N	(II);
Q-P-T-F-S-D-Y-W-K-L-L-P	(III)
P-X-F-X-D-Y-W-X-X-L	(IV).

As used herein, "peptide of the invention" refers to a linear compound comprising the amino acid motif of formula (I) and containing only natural amino acids which are linked by peptide bonds and which are in an unprotected form.

The present invention also provides derivatives of the peptides of the invention as defined above. Such derivatives may be linear or circular. Derivatives of the invention include molecules wherein a peptide of the invention is non-covalently or preferably covalently modified by substitution, chemical, enzymatic or other appropriate means with another atom or moiety including another peptide or protein. The moiety may be "foreign" to a peptide of

- 4 -

the invention as defined above in that it is an unnatural amino acid, or in that one or more, preferably one or two natural amino acid in the motif of formula (I) are replaced with another natural or unnatural amino acid. Conjugates comprising a peptide or derivative of the invention covalently attached to another peptide or protein are also encompassed here. Attachment of another moiety may involve a linker or spacer, e.g. an amino acid or peptide linker. Derivatives of the invention also includes peptides wherein one, some or all potentially reactive groups, e.g. amino, carboxy, sulfhydryl or hydroxyl groups are in a protected form.

The atom or moiety derivatizing a peptide of the invention may serve analytical purposes, e.g. facilitate detection of the peptide of the invention, favor preparation or purification of the peptide, or improve a property of the peptide which is relevant for the purposes of the present invention. Such properties include e.g. cellular uptake, binding to MDM2, or suitability for in vivo administration, particularly solubility or stability against enzymatic degradation. Derivatives of the invention include a covalent or aggregative conjugate of a peptide of the invention with another chemical moiety, said derivative displaying essentially the same activity as the underivatized peptide of the invention, and a "peptide analogue" or "mimetic" which is modelled to resemble the three-dimensional structure of the amino acid motif of formula (I). The designing of mimetics to a known pharmaceutically active compound is a known approach to the design of drugs based on a "lead" compound. This may be desirable e.g. where the "original" active compound is difficult or expensive to synthesise, or where it is unsuitable for a particular mode of administration, e.g. peptides are considered unsuitable active agents for oral compositions as they tend to be quickly degraded by proteases in the alimentary channel.

Examples of derivatives within the above general definitions are:

- Cyclic peptides or derivatives including compounds with a disulfide bridge, a thioether bridge or a lactam. Typically, cyclic derivatives containing a disulphide bond will contain two cysteines, which may be L-cysteine or D-cysteine. Advantageously, the N-terminal amino acid (e.g. R_1 in formula I) and the C-terminal amino acids are both cysteines. In such derivatives, As an alternative to cysteine, penicillamine (β,β -dimethyl-cysteine) can be used. Peptides containing thioether bridges are obtainable e.g. from starting compounds having a free cysteine residue at one end and a bromo-containing building block at the other end (e.g., bromo-acetic acid). Cyclisation can be carried out on solid phase by a selective deprotection of the side chain of cysteine. A cyclic lactam may be formed e.g. between the γ -carboxy group of glutamic acid and the ϵ -amino group of lysine. For example, cyclic lactams

- 5 -

according to the invention have a Glu at the N-terminus (e.g. R_1 in formula I) and a Lys at the C-terminus. As an alternative to glutamic acid, it is possible to use aspartic acid. As an alternative to lysine, ornithine or diaminobutyric acid may be employed. Also, it is possible to make a lactam between the side chain of aspartic acid or glutamic acid at the C-terminus and the α -amino group of the N-terminal amino acid. This approach is extendable to β -amino acids (e.g., β -alanine).

- Peptides of the invention, which are modified by substitution. In the sequence of formula (I) one or two amino acids are replaced with another natural or unnatural amino acid, e.g. with the respective D-analog, or a mimetic. For example, in a peptide, wherein R_3 is Phe or particularly Tyr, Phe or Tyr may be replaced with another building block, e.g. another proteinogenic amino acid, or a structurally related analogue. Also,
- Peptides of the invention labelled with an enzyme, a fluorescent marker, a chemiluminescent marker, a metal chelate, paramagnetic particles, biotin, or the like. In such derivatives, the peptide of the invention is bound to the conjugation partner directly or by way of a spacer or linker group, e.g. a (peptidic) hydrophilic spacer. Advantageously, the peptide is attached at the N- or C-terminal amino acid. For example, biotin may be attached to the N-terminus of a peptide of the invention via a serine residue or the tetramer SerGlySerGly.
- Peptides of the invention carrying one or more protecting groups at a (potentially) reactive (side group), such as amino-protecting group, e.g. acetyl, or a carboxy-protecting group. For example, the C-terminal carboxy group of a compound of the invention may be present in form of a carboxamide function. Suitable protecting groups are commonly known in the art and further exemplified hereinbelow. Such groups may be introduced e.g. to enhance the stability of the compound against proteolytic degradation. If desired, such protecting groups are removed.
- Peptides of the invention fused or attached to another protein or peptide, e.g. a another peptide facilitating cellular uptake, such as penetratin. An exemplary penetratin comprising derivative according to the invention is e.g. a peptide having the amino acid sequence: M-P-R-F-M-D-Y-E-G-L-N-R-Q-I-K-K-W-F-Q-N-R-R-M-K-W-K-K.
- Salts, especially acid addition salts, salts with bases or, where several salt-forming groups are present, mixed salts or internal salts. Preferred are pharmaceutically acceptable salts. However, it is also possible to use pharmaceutically unacceptable salts, e.g. for isolation or purification purposes.

- 6 -

Derivatives of a peptide of the invention also comprise fragments of such peptide which, as compared to a peptide of formula (I), consist of or comprise at least eight i.e. eight or nine, consecutive amino acids of said motif. Such fragments may be further derivatized as described in detail above. Preferred fragments include the following: P-A-F-T-H-Y-W-P, particularly, P-T-F-S-D-Y-W-P and P-R-F-M-D-Y-W-P.

Preferred derivatives of the invention are the derivatives used to exemplify the present invention, derivatives of the peptides above designated as being preferred, and derivatives of fragments as defined above.

A derivative according to the invention may involve one or multiple modifications as compared to a peptide of the invention, e.g. carry one or more of the above defined moieties. In other words, a derivative of the invention is intended to include compounds derivable from or based on a peptide of the invention or another derivative of the invention. The preferred derivatives of the invention are capable of binding to MDM2 and of selectively inhibiting or blocking the binding of MDM2 to the p53 protein.

The compounds of the invention have useful, in particular pharmacologically useful properties. For example, they are useful in the treatment of diseases that respond to the inhibition of the p53-MDM2 interaction. As used hereinbefore or hereinbelow, the term "compound of the invention" refers to both peptides and derivatives of the invention.

The ability of a test compound to inhibit interaction between MDM2 and p53 can be shown by assays commonly known in the art, or modifications of known assays readily apparent to a person of ordinary skill in the art. Suitable assays include e.g. a binding assay determining binding of a test compound, e.g. a compound of the invention, to MDM2, an *in vitro* transcription assay or an assay as described in European Patent Application 95810576.9. Assays may be performed qualitatively or quantitatively and require comparison to one or more suitable controls.

A preferred binding assay is a competitive binding assay. The principle underlying a competitive binding assay is generally known in the art. Briefly, such binding assay is performed by allowing a compound to be tested for its capability to compete with a known, suitably labeled ligand, e.g. MDM2 or p53 for the binding site at a target molecule, e.g. p53 or MDM2 (depending on which molecule is used as known ligand). A suitably labeled ligand is e.g. a radioactively labeled ligand or a ligand which can be detected by its optical properties, such as absorbance or fluorescence. After removing unbound ligand and test compound the amount of labeled ligand bound to the target protein is measured. If the amount of bound

- 7 -

ligand is reduced in the presence of the test compound, said compound is found to bind to the target molecule.

Further details of suitable assays are given in the Examples. For example, ELISA-type assays may be used wherein p53 or an appropriately labelled p53 peptide comprising the MDM2 binding site on p53 is immobilized and binding of MDM2 is competed for by a candidate inhibitor. Alternatively, MDM2 may be immobilized and binding of p53 is competed for by such candidate. Furthermore, an assay involving phage display of a candidate peptide, e.g. a phage ELISA assay, may be used.

Preferred compounds of the invention are superior to the peptide having the amino acid sequence QETFSDLWKLLP corresponding to the correct p53 wild-type sequence in their ability to selectively inhibit the binding of p53 and MDM2.

The compounds of the present invention can be readily prepared according to well-established, standard liquid or, preferably, solid-phase peptide synthesis methods, general descriptions of which are broadly available (see, for example, in J.M. Stewart and J.D. Young, Solid Phase Peptide Synthesis, 2nd edition, Pierce Chemical Company, Rockford, Illinois (1984), in M. Bodanzsky and A. Bodanzsky, The Practice of Peptide Synthesis, Springer Verlag, New York (1984); and Applied Biosystems 430A Users Manual, ABI Inc., Foster City, California), or they may be prepared in solution, by the liquid phase method or by any combination of solid-phase, liquid phase and solution chemistry, e.g. by first completing the respective peptide portion and then, if desired and appropriate, after removal of any protecting groups being present, by introduction of the residue X by reaction of the respective carbonic or sulfonic acid or a reactive derivative thereof.

Reactive derivatives of carbonic or sulfonic acids are preferably reactive esters, reactive anhydrides or reactive cyclic amides. Reactive carbonic acid or reactive sulfonic acid derivatives can also be formed in situ.

The reaction steps required e.g. for the synthesis of amide or sulfonamide bonds usually depend on the type of activation of the carboxylic or sulfo group participating in the reaction. The reactions normally run in the presence of a condensing agent or, when activating the carboxylic or sulfonic acids in the form of anhydrides, of an agent that binds the carboxylic or sulfonic acid formed. The reactions are especially carried out in a temperature range from -30 to +150 °C, preferably from +10 to +70 °C, and, most preferably, from +20 to +50 °C, if appropriate, in an inert gas atmosphere, e.g. under nitrogen or argon.

- 8 -

Synthesis proceeds in a stepwise, cyclical fashion by successively removing the NH_2 protecting group of the amino group to be reacted next and then coupling an activated fragment (e.g. an amino acid, di-, tri- or oligopeptide or a carboxylic acid or sulfonic acid, or a reactive derivative thereof, to the deprotected NH_2 (e.g. α - or β - NH_2). Preferably, activate the COOH group of the amino acid to be reacted or the carboxyl or sulfo group of the acid to be attached by the condensation reaction is effected

(i) directly with a carbodiimide, with a carbonyl compound such as carbonyldiimidazole; with 1,2-oxazolium compounds; with acylamino compounds such as 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline; with N-[(dimethylamino)-1H-1,2,3-triazolo[4,5-b]pyridin-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide (HATU); with an uronium compound such as 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (HBTU); or phosphonium compounds such as benzotriazol-1-yl-oxy-tris(dimethylamino)-phosphonium hexafluorophosphate (BOP) or benzotriazol-1-yl-oxy-pyrrolidino-phosphonium hexafluorophosphate (PyBOP);

(ii) via formation of the symmetric anhydride (obtainable, for example, by condensation of the corresponding acid in the presence of a carbodiimide or 1-diethylaminopropylene; symmetric anhydrides method), or an asymmetric anhydride, such as the respective carbonic or sulfonic acid bromide, chloride or fluoride, or

(iii) by formation of an "active ester", e.g. an amino- or amido ester, such as a 1-hydroxy-benzotriazole (HOBt) or N-hydroxysuccinimide ester, or an aryl ester, such as a penta-fluorophenyl, 4-nitrophenyl or 2,4,5-tetrachlorophenyl ester;

or by an appropriate combination of any of the reagents and reactions mentioned under (i) to (iii).

Useful acid binding agents that can be employed in the condensation reactions are, for example, alkaline metals, carbonates or bicarbonates, such as sodium or potassium carbonate or bicarbonate (if appropriate, together with a sulfate), or organic bases such as sterically hindered organic nitrogen bases, for example tri-lower alkylamines, such as N,N-diisopropyl-N-ethylamine, pyridine or N-methyl-pyrrolidin-2-one, which can be used alone or in any appropriate combination.

Reactive groups in the monomers or ligands or in the resin-bound or free intermediates resulting from one or more coupling steps can be protected by third groups as protecting groups that are customarily used in peptide synthesis. Examples of protecting groups, their introduction and their removal are, for example, described in standard works such as

- 9 -

"Protective groups in Organic Chemistry", Plenum Press, London, New York 1973; "Methoden der organischen Chemie", Houben-Weyl, 4. edition, Vol. 15/1, Georg-Thieme Verlag, Stuttgart 1974; Th. W. Greene, "Protective Groups in Organic Synthesis", John Wiley & Sons, New York 1981; Atherton et al., "Solid Phase Peptide Synthesis - A Practical Approach", IRL Press Oxford University, 1984; Jones, "The Chemical Synthesis of Peptides", Oxford Science Publications, Clarendon Press Oxford, 1991; and Bodanszky, "Peptide Chemistry", Springer Verlag Berlin, 1988. The term "protecting groups" comprises also resins used for solid phase synthesis, preferably those specifically mentioned above and below.

Examples for hydroxy protecting groups are acyl radicals, such as tert-lower alkoxy-carbonyl radicals, for example tert-butoxycarbonyl, etherifying groups, such as tert-lower alkyl groups, for example t-butyl, or silyl- or tin radicals, such as tert-butyl-dimethylsilyl or the tri-n-butyltin radical.

Carboxy groups can be protected by groups as defined above for the C-terminal protecting groups Y, preferably by esterifying groups selected from those of the tert-butyl type, from benzyl, from trimethylsilylethyl and from 2-triphenylsilyl groups, or they can be protected as lower alkenyl esters, such as allylic esters.

Amino or guanidino (e.g. in H-Arg-OH) groups can be protected by removable acyl groups or by arylmethyl, etherified mercapto, 2-acyl-lower alk-1-enyl, a silyl group or an organic sulfonyl group or tin amino protecting groups; tert-butoxycarbonyl, allyloxycarbonyl, benzyl-oxycarbonyl, 4-nitrobenzyloxycarbonyl, 2-chlorobenzyloxycarbonyl, 2-bromobenzyloxy-carbonyl, diphenylmethoxycarbonyl, nitrophenylsulfonyl, 2,2,2-trichloroethoxycarbonyl, 2,2,5,7,8-pentamethylchroman-6-sulfonyl (PMC - very preferred), 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl (Pbf) or 4-methoxy-2,3,6-trimethylbenzenesulfonyl (Mtr) being especially preferred.

Carbamide groups (for example, in the side chains of asparagine and glutamine) can be protected at the nitrogen atom by arylmethyl groups, preferably triphenylmethyl (trityl) or analogues thereof with one or more lower alkoxy, such as methoxy, and/or lower alkyl, such as methyl, substituents in one or more phenyl rings.

Imino groups (e.g. in imidazole) can be protected by 2,4-dinitrophenyl, trityl, tert-butoxycarbonyl or p-toluenesulfonyl, or (e.g. in indole) by formyl or tert-butoxycarbonyl.

Mercapto groups can be protected, e.g., by acetamidomethyl, by trityl or by p-methylbenzyl.

- 10 -

A large number of methods of removing protective groups in the final products or any inter-mediate are known in the art and comprise, inter alia, β -elimination, solvolysis, hydrolysis, alcoholysis, acidolysis, photolysis, enzymatical removal, treatment with a base or reduction.

The protective groups are usually removed after the complete synthesis of the resin-bound molecule by conventional methods of peptide chemistry, conveniently by treatment with 95 % trifluoroacetic acid (Fmoc-chemistry). In some cases, strong nucleophiles, such as dimethyl sulfide and/or 2-ethanedithiol, may be additionally added to capture the generated compounds resulting from the protecting groups, e.g. in a combination such as trimethylsilyltrifluoro-methanesulfonate/dimethylsulfide/trifluoroacetic acid/ethanedithiol/m-cresol.

The two preferred methods of solid phase peptide synthesis are the Boc and the Fmoc methods, which are named with reference to their use of the tert-butoxycarbonyl (Boc) or 9-fluorenylmethyloxycarbonyl (Fmoc) group, respectively, to protect the α -NH₂ or α -NHR₃ of the amino acid residue to be coupled (see J. M. Stewart, J. D. Young, Solid-Phase Peptide Synthesis, 2nd edn., Pierce, Rockford, Illinois (1984) or G. Barany, R.B. Merrifield, Solid-phase Peptide Synthesis, in: The Peptides, Vol. 2 (E. Gross, J. Meienhofer, eds.), Academic Press, New York (1979)); and E. Atherton and R.C. Sheppard, in Solid-Phase Peptide Synthesis-A Practical Approach, ed. D. Rickwood and B.D. Hames, IRL Press at Oxford University Press, Oxford, 1989), respectively).

Derivatives of the invention are prepared according to conventional methods involving de novo synthesis or starting from a peptide or another derivative of the invention.

In another aspect, the present invention provides a method for interfering with the binding between p53 and MDM2, which method comprises administering an effective amount of a compound of the invention.

Furthermore, the present invention relates to uses of a compound of the invention including its use in the purification of a binding partner, particularly MDM2; its use as a "lead compound" for drug development or design; its use in a method of identifying compounds which interfere with the binding of MDM2 to p53; its use in diagnosis, e.g. to measure the levels of MDM2 in blood samples in the case of leukaemias or solid carcinomas, such as sarcomas or glioblastomas.

The invention relates also to pharmaceutical compositions comprising compounds of the invention, to their use in the therapeutic (including prophylactic) treatment of the

- 11 -

hyperproliferative diseases and viral infections, to the compounds for said use and to the preparation of pharmaceutical preparations.

The pharmacologically acceptable compounds of the present invention may be used, for example, for the preparation of pharmaceutical compositions that comprise an effective amount of the active ingredient together or in admixture with a significant amount of inorganic or organic, solid or liquid, pharmaceutically acceptable carriers.

The invention provides a pharmaceutical composition that is suitable for administration to a warm-blooded animal, especially a human (or to cells or cell lines derived from a warm-blooded animal, especially a human, e.g. lymphocytes), for the treatment or prevention of (= prophylaxis against) a disease that responds to inhibition of the interaction of p53 with MDM2, comprising an amount of a peptide of the invention or a pharmaceutically acceptable derivative thereof, which is effective for said inhibition, together with at least one pharmaceutically acceptable carrier.

The pharmaceutical compositions according to the invention are those for enteral, such as nasal, rectal or oral, or parenteral, such as intramuscular or intravenous, administration to warm-blooded animals (humans and animals), that comprise an effective dose of the pharmacologically active ingredient, alone or together with a significant amount of a pharmaceutically acceptable carrier. The dose of the active ingredient depends on the species of warm-blooded animal, the body weight, the age and the individual condition, individual pharmacokinetic data, the disease to be treated and the mode of administration.

The invention relates also to a method of treating diseases that respond to inhibition of the interaction of MDM2 and p53, which comprises administering a prophylactically or especially therapeutically effective amount of a peptide or derivative according to the invention, especially to a warm-blooded animal, for example a human, that, on account of one of the mentioned diseases, requires such treatment.

The pharmaceutical compositions comprise from approximately 1 % to approximately 95%, preferably from approximately 20 % to approximately 90%, active ingredient. Pharmaceutical compositions according to the invention may be, for example, in unit dose form, such as in the form of ampoules, vials, suppositories, dragées, tablets or capsules.

The pharmaceutical compositions of the present invention are prepared in a manner known *per se*, for example by means of conventional dissolving, lyophilising, mixing, granulating or confectioning processes.

- 12 -

Solutions of the active ingredient, and also suspensions, and especially isotonic aqueous solutions or suspensions, are preferably used, it being possible, for example in the case of lyophilised compositions that comprise the active ingredient alone or together with a carrier, for example mannitol, for such solutions or suspensions to be produced prior to use. The pharmaceutical compositions may be sterilised and/or may comprise excipients, for example preservatives, stabilisers, wetting and/or emulsifying agents, solubilisers, salts for regulating the osmotic pressure and/or buffers, and are prepared in a manner known *per se*, for example by means of conventional dissolving or lyophilising processes. The said solutions or suspensions may comprise viscosity-increasing substances, such as sodium carboxymethylcellulose, carboxymethylcellulose, dextran, polyvinylpyrrolidone or gelatin.

Suspensions in oil comprise as the oil component the vegetable, synthetic or semi-synthetic oils customary for injection purposes. There may be mentioned as such especially liquid fatty acid esters that contain as the acid component a long-chained fatty acid having from 8 to 22, especially from 12 to 22, carbon atoms, for example lauric acid, tridecyl acid, myristic acid, pentadecyl acid, palmitic acid, margaric acid, stearic acid, arachidic acid, behenic acid or corresponding unsaturated acids, for example oleic acid, elaidic acid, erucic acid, brassidic acid or linoleic acid, if desired with the addition of antioxidants, for example vitamin E, β -carotene or 3,5-di-*tert*-butyl-4-hydroxytoluene. The alcohol component of those fatty acid esters has a maximum of 6 carbon atoms and is a mono- or poly-hydroxy, for example a mono-, di- or tri-hydroxy, alcohol, for example methanol, ethanol, propanol, butanol or pentanol or the isomers thereof, but especially glycol and glycerol. The following examples of fatty acid esters are therefore to be mentioned: ethyl oleate, isopropyl myristate, isopropyl palmitate, "Labrafil M 2375" (polyoxyethylene glycerol trioleate, Gattefossé, Paris), "Miglyol 812" (triglyceride of saturated fatty acids with a chain length of C₈ to C₁₂, Hüls AG, Germany), but especially vegetable oils, such as cottonseed oil, almond oil, olive oil, castor oil, sesame oil, soybean oil and more especially groundnut oil.

The injection compositions are prepared in customary manner under sterile conditions; the same applies also to introducing the compositions into ampoules or vials and sealing the containers.

Pharmaceutical compositions for oral administration can be obtained by combining the active ingredient with solid carriers, if desired granulating a resulting mixture, and processing the mixture, if desired or necessary, after the addition of appropriate excipients, into tablets,

- 13 -

dragée cores or capsules. It is also possible for them to be incorporated into plastics carriers that allow the active ingredients to diffuse or be released in measured amounts.

Suitable carriers are especially fillers, such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, and binders, such as starch pastes using for example corn, wheat, rice or potato starch, gelatin, tragacanth, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, and/or, if desired, disintegrators, such as the above-mentioned starches, also carboxymethyl starch, crosslinked polyvinylpyrrolidone, agar, alginic acid or a salt thereof, such as sodium alginate. Excipients are especially flow conditioners and lubricants, for example silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and/or polyethylene glycol. Dragée cores are provided with suitable, optionally enteric, coatings, there being used, *inter alia*, concentrated sugar solutions which may comprise gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and/or titanium dioxide, or coating solutions in suitable organic solvents, or, for the preparation of enteric coatings, solutions of suitable cellulose preparations, such as ethylcellulose phthalate or hydroxypropylmethylcellulose phthalate. Capsules are dry-filled capsules made of gelatin and soft sealed capsules made of gelatin and a plasticiser, such as glycerol or sorbitol. The dry-filled capsules may comprise the active ingredient in the form of granules, for example with fillers, such as lactose, binders, such as starches, and/or glidants, such as talc or magnesium stearate, and if desired with stabilisers. In soft capsules the active ingredient is preferably dissolved or suspended in suitable oily excipients, such as fatty oils, paraffin oil or liquid polyethylene glycols, it being possible also for stabilisers and/or antibacterial agents to be added. Dyes or pigments may be added to the tablets or dragée coatings or the capsule casings, for example for identification purposes or to indicate different doses of active ingredient.

The following Examples serve to illustrate the present invention, but should not be construed as a limitation thereof. The invention particularly relates to the specific embodiments (e.g. peptides, methods for their preparation, and assays as described in these Examples.

Abbreviations: Aorid = thioether resulting from the reaction of a Cys-sulfhydryl group in the peptide with 6-acryloyl-2-(dimethylamino)naphthalene; o/n = overnight.

Examples

- 14 -

Example 1: Synthesis of N-acylated peptide derivatives

The below-identified peptides are synthesised on a Milligen 9050 automated peptide synthesizer (continuous flow; Millipore, Bedford, MA, USA), starting with an Fmoc-PAL-PEG-PS resin (see Albericio, F. et al, J. Org. Chem., 55 (1990) 3730-3743) for establishing the terminal carboxamide, and using chemical protocols based on the fluorenylmethoxycarbonyl chemistry (see E. Atherton and R.C. Sheppard, in Solid-Phase Peptide Synthesis-A Practical Approach, eds: R. Rickwood and B.D. Hames, IRL Press at Oxford University Press, Oxford, 1989). The required Fmoc-amino acids (3 equivalents) are incorporated using their 2,4,5-trichlorophenyl esters (single coupling) with minimum reaction times of 30 min (see 9050 Plus PepSynthesizer User's Guide, Millipore Corporation, Bedford, MA, 1992). Side chains are protected with the following groups:

tert-butyl for aspartic acid, glutamic acid, tyrosine, serine and threonine;

tert-butoxycarbonyl for lysine and tryptophan;

2,2,5,7,8-pentamethyl-chroman-6-sulfonyl for arginine;

trityl for histidine, cysteine, asparagine, and glutamine.

The complete peptide resins obtained after the final coupling reaction are simultaneously deprotected and cleaved by treatment with trifluoroacetic acid/water/ethanedithiol (76:4:20, v/v/v) for 3 h at room temperature. The filtrate from each cleavage reaction is precipitated in diisopropyl ether-petroleum ether (1:1, v/v) at 0°C, and the precipitates are collected by filtration. The crude compounds are dissolved in 2N AcOH/acetonitrile (1:1, v/v) to remove the *N*ⁱⁿ-carboxy group from the side chain of tryptophan. The course of the reactions is monitored by analytical reversed-phase HPLC. After 2 h at 40°C, the solutions are concentrated to dryness and the crude peptides are purified by reversed-phase medium-pressure liquid chromatography using a C₁₈ column eluted with an acetonitrile-water gradient containing 0.1% trifluoroacetic acid (Merck LICHROPREP RP-18, 15-25 µm bead diameter, reversed phase column material based on C₁₈-derivatised silicagel, Merck, Darmstadt, FRG; column length 46 cm, diameter 3.8 cm; flow rate 53.3 ml/min; detection at 215 nm). Mass spectrometric analyses (matrix-assisted laser-desorption ionization time-of-flight mass spectrometry, MALDI-TOF) reveal molecular masses within 0.1% of the expected values (positive or negative ion mode). Quantitative amino acid analyses of the final products reveal amino acid compositions within 5% of the expected values. The purity of the peptides is verified by reversed-phase analytical HPLC on a Nucleosil column (250 x 4.0 mm; 5 µm, 100): linear gradient over 10 min of MeCN/0.09% TFA and H₂O/0.1% TFA from 1:49 to 3:2; flow rate 2.0 ml/min, detection at 215 nm (HPLC System A); HPLC System B: linear gradient over 10 min of MeCN/0.09% TFA and H₂O/0.1% TFA from 1:49 to 1:0; flow rate 2.0 ml/min, detection at 215 nm.

- 15 -

The peptides are as follows:

- Ac-Thr-Gly-Pro-Ala-Phe-Thr-His-Tyr-Trp-Ala-Thr-Phe-NH₂ (TFA salt);
Mass spectral analysis (negative-ion mode): 1441.7 (calc. 1441.6, C₇₁H₉₂N₁₆O₁₇),
t_R (retention time) = 8.08 min (HPLC System A).
- Ac-Met-Pro-Arg-Phe-Met-Asp-Tyr-Trp-Glu-Gly-Leu-Asn-NH₂ (TFA salt);
Mass spectral analysis (negative-ion mode): 1598.9 (calc. 1598.9, C₇₃H₁₀₁N₁₈O₁₉S₂),
t_R = 8.82 min (HPLC System A).
- Ac-Gln-Pro-Thr-Phe-Ser-Asp-Tyr-Trp-Lys-Leu-Leu-Pro-NH₂ (TFA salt);
Mass spectral analysis (negative-ion mode): 1534.8 (calc. 1534.8, C₇₅H₁₀₅N₁₆O₁₉),
t_R = 8.73 min (HPLC System A).
- Ac-Pro-Ala-Phe-Thr-His-Tyr-Trp-Pro-NH₂ (TFA salt);
Mass spectral analysis (negative-ion mode): 1060.3 (calc. 1060.2, C₅₄H₆₇N₁₂O₁₁),
t_R = 8.21 min (HPLC System A).
- Ac-Pro-Thr-Phe-Ser-Asp-Tyr-Trp-Pro-NH₂ (TFA salt)
Mass spectral analysis (negative-ion mode): 1052.0 (calc. 1052.1, C₅₂H₆₃N₁₀O₁₄),
t_R = 7.97 (HPLC System A).
- Ac-Pro-Arg-Phe-Met-Asp-Tyr-Trp-Pro-NH₂ (TFA salt);
Mass spectral analysis (negative-ion mode): 1151.6 (calc. 1151.3, C₅₆H₇₂N₁₃O₁₂S₁),
t_R = 8.42 (HPLC System A).
- Ac-Gln-Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu-Pro-NH₂ (TFA salt)
Mass spectral analysis (negative-ion mode): 1517.1 (calc. 1516.8, C₇₂H₁₀₇N₁₆O₂₀),
t_R = 9.30 (HPLC System A), t_R = 6.65 (HPLC System B)
- Ac-Gln-Pro-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu-Pro-NH₂ (TFA salt)
Mass spectral analysis (negative-ion mode): 1485.0 (calc. 1484.8, C₇₂H₁₀₇N₁₆O₁₈),
t_R = 9.32 (HPLC System A), t_R = 6.66 (HPLC System B)
- Ac-Gln-Glu-Thr-Phe-Ser-Asp-Tyr-Trp-Lys-Leu-Leu-Pro-NH₂ (TFA salt)
Mass spectral analysis (negative-ion mode): 1567.3 (calc. 1566.8, C₇₅H₁₀₅N₁₆O₂₁),
t_R = 8.55 (HPLC System A), t_R = 6.19 (HPLC System B).
- Ac-Val-Gln-Asn-Phe-Ile-Asp-Tyr-Trp-Thr-Gln-Gln-Phe-NH₂
Mass spectral analysis (negative-ion mode): 1628.8 (calc. 1628.8, C₇₈H₁₀₃N₁₈O₂₁),
t_R = 7.03 (HPLC System A);
- Ac-Gln-Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu-Pro-NH₂ (TFA salt);
Mass spectral analysis (negative-ion mode): 1517.1 (calc. 1516.8, C₇₂H₁₀₇N₁₆O₂₀),
t_R = 9.30 (HPLC System A); t_R = 6.65 (HPLC System B).
- Ac-Val-Gln-Asn-Phe-Ile-Asp-Tyr-Trp-Thr-Gln-Gln-Phe-NH₂

- 16 -

Mass spectral analysis (negative-ion mode): 1628.4 (calc. 1628.8, C₇₈H₁₀₃N₁₈O₂₁), t_R= 7.03 min (HPLC System A); t_R= 7.03 min (HPLC System B).

- Ac-Thr-Gly-Pro-Ala-Phe-Thr-His-Tyr-Trp-Ala-Thr-Phe-NH₂ (TFA salt)

Mass spectral analysis (positive-ion mode): 1440.9 (calc. 1440.6, C₇₁H₉₁N₁₆O₁₇), t_R= 8.38 min (HPLC System A).

- Ac-Ile-Asp-Arg-Ala-Pro-Thr-Phe-Arg-Asp-His-Trp-Phe-Ala-Leu-Val-NH₂ (TFA salt)

Mass spectral analysis (negative-ion mode): 1883.9 (calc. 1884.2, C₈₉H₁₂₈N₂₅O₂₁), t_R= 8.57 min (HPLC System A)

- Ac-Pro-Arg-Pro-Ala-Leu-Val-Phe-Ala-Asp-Tyr-Trp-Glu-Thr-Leu-Tyr-NH₂ (TFA salt)

Mass spectral analysis (negative-ion mode): 1881.6 (calc. 1881.2, C₉₂H₁₂₇N₂₀O₂₃), t_R= 9.58 min (HPLC System A); t_R= 6.88 min (HPLC System B).

- Ac-Pro-Ala-Phe-Ser-Arg-Phe-Trp-Ser-Asp-Leu-Ser-Ala-Gly-Ala-His-NH₂ (TFA salt)

Title compound: Mass spectral analysis (negative-ion mode): 1688.6 (calc. 1688.9, C₇₈H₁₀₇N₂₂O₂₁), t_R= 9.09 min (HPLC System A); t_R= 6.48 min (HPLC System B)

If desired, the acylated peptide derivatives are de-acylated to generate a free N-terminal amino group. Peptides with a free N-terminal amino group include:

- H-Thr-Gly-Pro-Ala-Phe-Thr-His-Tyr-Trp-Ala-Thr-Phe-NH₂ (TFA salt)

Mass spectral analysis (negative-ion mode): 1396.6 (calc. 1396.6, C₆₉H₈₇N₁₆O₁₆), t_R= 7.86 min (HPLC System A).

- H-Met-Pro-Arg-Phe-Met-Asp-Tyr-Trp-Glu-Gly-Leu-Asn-NH₂ (TFA salt)

Mass spectral analysis (negative-ion mode): 1556.6 (calc. 1556.8, C₇₁H₉₉N₁₈O₁₈S₂), t_R= 7.92 min (HPLC System A).

Example 2: Synthesis of Cys(Acrld) peptide derivatives

1. Ac-Cys(Acrld)-Gly-Gln-Pro-Thr-Phe-Ser-Asp-Tyr-Trp-Lys-Leu-Leu-Pro-NH₂ (TFA salt)

Ac-Cys-Gly-Gln-Pro-Thr-Phe-Ser-Asp-Tyr-Trp-Lys-Leu-Leu-Pro-NH₂ (TFA salt) is obtained analogously to Example 1 (Mass spectral analysis (negative-ion mode): 1694.7 (calc. 1695.0, C₈₀H₁₁₃N₁₈O₂₁S₁), t_R= 8.39 (HPLC System A)).

To a solution of Ac-Cys-Gly-Gln-Pro-Thr-Phe-Ser-Asp-Tyr-Trp-Lys-Leu-Leu-Pro-NH₂ (18 μmol) in 20 ml of degassed phosphate buffer (pH= 7.5) is added 6-acryloyl-2-(dimethylamino)naphtalene (2-fold excess; Molecular Probes, Inc., Leiden, The Netherlands) dissolved in 2 ml of acetonitrile. The solution is stirred overnight at room temperature under an argon atmosphere. After completion of the reaction, 1 ml of trifluoroacetic acid is added and the solution is concentrated to dryness. The compound is purified by reversed-phase medium-pressure liquid chromatography.

- 17 -

Title compound: Mass spectral analysis (negative-ion mode): 1920.4 (calc. 1920.3, $C_{95}H_{128}N_{19}O_{22}S_1$), t_R = 9.20 (HPLC System A); t_R = 8.60 (HPLC System B).

I. Ac-Cys(Acrd)-Gly-Pro-Thr-Phe-Ser-Asp-Leu-Trp-Pro-NH₂ (TFA salt)

Ac-Cys-Gly-Pro-Thr-Phe-Ser-Asp-Leu-Trp-Pro-NH₂ (TFA salt) is obtained analogously to Example 1 (Mass spectral analysis (negative-ion mode): 1162.0 (calc. 1162.3, $C_{54}H_{73}N_{12}O_{15}S_1$), t_R = 8.00).

The title compound (II) is obtained analogously to the previous example (I).

Title compound: Mass spectral analysis (negative-ion mode): 1387.6 (calc. 1387.6, $C_{68}H_{88}N_{13}O_{16}S_1$), t_R = 9.63 (HPLC System A), t_R = 6.87 (HPLC System B).

III. Ac-Cys(Acrd)-Pro-Thr-Phe-Ser-Asp-Leu-Trp-Pro-NH₂ (TFA salt)

Ac-Cys-Pro-Thr-Phe-Ser-Asp-Leu-Trp-Pro-NH₂ (TFA salt) is obtained analogously to Example 1. (Mass spectral analysis (negative-ion mode): 1105.5 (calc. 1105.3, $C_{52}H_{70}N_{11}O_{14}S_1$), t_R = 8.25 (HPLC System A).

The title compound is obtained analogously to the above example.

Title compound: Mass spectral analysis (negative-ion mode): 1330.6 (calc. 1330.6, $C_{67}H_{85}N_{12}O_{15}S_1$), t_R = 9.82 (HPLC System A); t_R = 7.02 (HPLC System B).

Example 3: Synthesis of biotinylated peptide derivatives

- Biotin-Ser-Gly-Ser-Gly-Gln-Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu-Pro-NH₂ (TFA salt)

(+)-Biotin (3 equivalents; Fluka, Buchs, Switzerland) is coupled with N-[(dimethylamino)1H-1,2,3-triazolo[4,5-b]pyridin-1-ylmethylene]-N-methylmethan-aminium hexafluorophosphate N-oxide (3 equiv.; double coupling; PerSeptive Biosystems, Hamburg, Germany) in the presence of diisopropylethylamine (6 equiv.)

Mass spectral analysis (negative-ion mode): 1989.5 (calc. 1989.3, $C_{90}H_{135}N_{22}O_{27}S_1$), t_R = 9.02 (HPLC System A), t_R = 6.55 (HPLC System B)

- Biotin-Ser-Gly-Ser-Gly-Gln-Pro-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu-Pro-NH₂ (TFA salt).

Mass spectral analysis (negative-ion mode): 1957.9 (calc. 1957.3, $C_{90}H_{135}N_{22}O_{25}S_1$), t_R = 9.04 (HPLC System A), t_R = 6.57 (HPLC System B).

- Biotin-Ser-Gly-Ser-Gly-Gln-Glu-Thr-Phe-Ser-Asp-Tyr-Trp-Lys-Leu-Leu-Pro-NH₂ (TFA salt).

Mass spectral analysis (negative-ion mode): 2039.3 (calc. 2039.3, $C_{93}H_{133}N_{22}O_{28}S_1$), t_R = 8.46 (HPLC System A).

- 18 -

- Biotin-Ser-Met-Pro-Arg-Phe-Met-Asp-Tyr-Trp-Glu-Gly-Leu-Asn-Arg-Gln-Ile-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Trp-Lys-Lys-NH₂ (TFA salt)

Mass spectral analysis (negative-ion mode): 4098.4 (calc. 4099.0, C₁₈₈H₂₈₄N₅₅O₄₁S₄), t_R = 9.08 min (HPLC System A); t_R = 6.41 min (System B). This derivative comprises a ' label, serine as spacer, a peptide of the invention and the penetratin sequence Arg-Gln-Lys-Ile-Trp-Phe-Gln-Asn-Arg-Arg-Met-Trp-Lys-Lys.

Example 4: Cyclic peptide derivatives containing disulphide bond

Cyclic peptides containing a disulphide bond are synthesized from the respective cysteinyl peptides as follows: the cysteinyl peptide (20 mg; in the following referred to as starting compound) is dissolved in a 0.1 M solution of ammonium bicarbonate (20 ml). The mixture is left to stand open to atmosphere. Aliquots of the solution are removed at different times and analysed by analytical HPLC. After 24 h, the reaction mixture is concentrated to dryness. The crude compound is dissolved in water and injected directly in a medium-pressure liquid chromatography system as described above, and the title compound is obtained.

Ac-Cys-Thr-Phe-Ser-Asp-Tyr-Trp-Cys-NH₂ (TFA salt) is obtained analogously to Example 1. Starting compound: Mass spectral analysis (negative-ion mode): 1064.6 (calc. 1064.2, C₄₈H₆₉N₁₀O₁₄S₂), t_R = 8.15 (HPLC System A).

- Ac-Cys-Thr-Phe-Ser-Asp-Tyr-Trp-Cys-NH₂



Title compound: Mass spectral analysis (negative-ion mode): 1062.2 (calc. 1062.2, C₄₈H₆₇N₁₀O₁₄S₂), t_R = 7.96 (HPLC System A).

Ac-Cys-Ala-Phe-Thr-His-Tyr-Trp-Cys-NH₂ (TFA salt);

Starting compound: Mass spectral analysis (negative-ion mode): 1070.0 (calc. 1070.2, C₅₀H₆₁N₁₂O₁₁S₂), t_R = 8.35 (HPLC System A).

- Ac-Cys-Ala-Phe-Thr-His-Tyr-Trp-Cys-NH₂ (TFA salt)



Mass spectral analysis (positive-ion mode): 1070.4 (calc. 1070.2, C₅₀H₆₁N₁₂O₁₁S₂), t_R = 8.13 min (HPLC System A).

Ac-Cys-Arg-Phe-Met-Asp-Tyr-Trp-Cys-NH₂ (TFA salt)

Starting compound: Mass spectral analysis (negative-ion mode): 1163.7 (calc. 1163.4, C₅₂H₆₈N₁₃O₁₂S₃), t_R = 8.67 (HPLC System A).

- Ac-Cys-Arg-Phe-Met-Asp-Tyr-Trp-Cys-NH₂ (TFA salt)

- 19 -

S-----S

Mass spectral analysis (negative-ion mode): 1161.1 (calc. 1161.4, C₅₂H₆₆N₁₃O₁₂S₃). t_R = 8.33 min (HPLC System A).

As an alternative to cysteine, penicillamine (β,β-dimethyl-cysteine) can be used. Also, L-cysteine may be changed for D-cysteine either at the N- or C- terminus, or in both sides. Peptides containing thioether bridges are formed from starting compounds having a free cysteine residue at the C-terminus and a bromo-containing building block at the N-terminus (e.g., bromo-acetic acid). Cyclisation can be carried out on solid phase by a selective deprotection of the side chain of cysteine (Mayer, J.P. et al., Tetrahedron Lett. 361411, 7387-7390 (1995)).

Example 5: Synthesis of lactam peptide derivatives

The peptide is synthesised manually on a 4-(2',4'-dimethoxyphenyl-aminomethyl)-phenoxy-resin (Novabiochem, Läufelfingen, Switzerland), employing the fluorenylmethoxycarbonyl strategy. Fmoc-removal is with piperidine/dimethylacetamide (1:4, v/v; 6 x 2 min), followed by washing with methanol (3 x 1 min), N-methylpyrrolidin-2-one (2 x 1 min), methanol (3 x 1 min), and N-methylpyrrolidin-2-one (3 x 2 min). Amino acid side chains are protected with the following groups: *tert*-butyl for threonine and tyrosine; trityl for histidine; *tert*-butyloxycarbonyl for tryptophan; allyl for glutamic acid; and allyloxycarbonyl for lysine. The required Fmoc-derivatives of tryptophan, tyrosine, histidine, threonine, phenylalanine and alanine are incorporated using their 2,4,5-trichlorophenyl esters (2 equiv.) in the presence of 1-hydroxybenzotriazole (2 equiv.) and diisopropylethylamine (0.75 equiv.). The incorporation of N^α-Fmoc-Lys(Aloc)-OH (2 equiv.; PerSeptive Biosystems, Hamburg, Germany) and N^α-Fmoc-Glu(OAll)-OH (2 equiv.; Millipore, Bedford, MA, U.S.A.) is accomplished with benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphoniumhexafluorophosphate/1-hydroxybenzotriazole (1:1; 2 equiv.) in the presence of diisopropylethylamine (4 equiv.). Coupling is achieved by first dissolving the Fmoc-amino acid, diisopropylethylamine, and the coupling reagent in N-methylpyrrolidin-2-one, then waiting 3 min for preactivation, adding the mixture to the resin, and finally shaking for at least 45 min. After the incorporation of the last residue, the side chains of glutamic acid and lysine are selectively deprotected with tetrakis(triphenylphosphine) palladium (0) (Fluka, Buchs, Switzerland) in the presence of trimethylsilylacetate and 4-(trimethylsilyl)morpholine dissolved in dichloromethane. The deprotection is carried out in an argon atmosphere for 2h at room temperature, followed by washing with dichloromethane (4 x 1 min), N-methylpyrrolidin-2-one (4 x 1 min), 0.05 M sodium diethyldithiocarbamate in DMF containing 0.5% of diisopropylethylamine (4 x 1 min),

- 20 -

and *N*-methylpyrrolidin-2-one (4 x 1 min). Intramolecular cyclisation on the solid support is accomplished with benzotriazole-1-yl-oxy-tris-(dimethylamino)-phosphoniumhexafluorophosphate/1-hydroxybenzotriazole (1:1; 6 equiv.; double coupling) in the presence of diisopropylethylamine (12 equiv.). The complete peptide resin obtained after the cyclisation step is simultaneously deprotected and cleaved by treatment with trifluoroacetic acid/water/ethanedithiol (76:4:20, v/v/v) for 3 h at room temperature. The filtrate is precipitated in diisopropyl ether-petroleum ether (1:1, v/v) at 0° C, and the precipitate is collected by filtration. The crude compound is dissolved in 2N AcOH/acetonitrile (1:1, v/v) to remove the *N*ⁱⁿ-carboxy group from the side chain of tryptophan. The courses of the reactions are monitored by analytical reversed-phase HPLC. After 2 h at 40 °C, the solution is concentrated to dryness and the crude peptide is purified by medium-pressure liquid chromatography as described above.

- Ac-Glu-Thr-Phe-Ser-Asp-Tyr-Trp-Lys-NH₂ (TFA salt)
 ---CO-NH---

Mass spectral analysis (negative-ion mode): 1097.5 (calc. 1097.2, C₅₃H₆₆N₁₁O₁₅),
 t_R = 7.49 min (HPLC System A).

- Ac-Glu-Arg-Phe-Met-Asp-Tyr-Trp-Lys-NH₂ (TFA salt)
 ---CO-NH---

Mass spectral analysis (negative-ion mode): 1196.7 (calc. 1196.4, C₅₇H₇₅N₁₄O₁₃S₁),
 t_R = 8.09 min (HPLC System A).

As an alternative to glutamic acid, it is possible to use aspartic acid. As an alternative to lysine, ornithine or diaminobutyric acid may be used. As an alternative to side-side cyclisation, it is possible to make a lactam between the side chain of aspartic acid or glutamic acid at the C-terminus and the α-amino group of the N-terminal amino acid. This approach can also be expanded to β-amino acids (e.g., β-alanine).

Example 6: Fluorescence assay

The DNA region of the mdm2 gene encoding the first 188 amino acids of the protein is obtained by Polymerase Chain Reaction (PCR) amplification of the mdm2 gene. The oligonucleotides used for PCR are designed such that a BamHI restriction site is introduced at the 5' extremity of the gene and an EcoRI restriction site at its 3' end. The PCR fragments digested by BamHI and EcoRI are ligated with a BamHI / EcoRI cleaved pGEX-2T vector. The resulting vector comprises a fusion gene consisting of the full length sequence of glutathione-S-transferase of *S. japonicum*, a linker

- 21 -

sequence, and the N-terminal 188 amino acids of HDM2, in the 5' to 3' order. The complete gene is sequenced on both strands and the recombinant plasmid is introduced into *E. coli* strain BL21 (Novagen).

Glutathione-S-transferase protein (for control experiments) is obtained from *E. coli* strain BL21 (Novagen) transformed with pGEX-2T plasmid.

The test compound ($c = 50$ nM), e.g. a fluorogenic peptide described in Example 4, is titrated with different amounts of the GST-hdm2 protein ($c = 0, 50$ nM, 200 nM, and 300 nM). The fluorescence emission spectra ($\lambda_{ex} = 370$ nm) are recorded in a spectrofluorophotometer at 20°C. The instrument setting during the titration is identical so that the fluorescence intensities in the presence or absence of the GST-hdm2 protein can be compared. A stock solution of the fluorogenic peptide is prepared in a PBS buffer (pH = 7.6) containing 10% glycerol, 1% Triton 100, 50 mM NaCl and BSA (1 mg/ml). The peptide ($c = 50$ nM) is incubated for 30 min with different amounts of the GST-hdm2 protein. After this time, the fluorescence emission spectrum is recorded. The addition of the GST-hdm2 protein to the solution containing the fluorogenic peptide results in an increase in the emission fluorescence of the fluorogenic peptide at 530 nm. The fluorescence emission spectra of the GST-hdm2 protein ($c = 50-300$ nM) is identical to the fluorescence emission spectra of the buffer, so the protein does not contribute to the observed increase in emission fluorescence.

This assay is applicable to the detection of specific interactions of peptides or low molecular weight compounds with the MDM2 protein. In addition, it allows accurate kinetic measurements in solution.

Example 7: Identification of MDM2 binding peptides by phage display

In deviation from the previous definition, in the following Examples "hdm2" refers to the human double minute gene2 and the corresponding protein.

Phage selection

The phage libraries used in this study display random peptide sequences of six, twelve or fifteen amino acid residues at the N-terminus of the minor coat protein III. These libraries are provided by George Smith (University of Missouri, 6 and 15mer) and William Dower (Affymax Research Institute, 12mer). In a biopanning procedure library samples are screened on solid phase GST-hdm2 (hdm2 comprising amino acids 1-188). Polystyrene petri dishes (Falcon 3001) are coated with 5 µg/ml GST-hdm2 or DO- 1 (monoclonal anti-p53 antibody) overnight

- 22 -

at 4°C in a humidity chamber. Unbound material is washed off with 2.5ml PBS and the dishes are blocked with 2ml TBST-M (150mM NaCl, 50mM Tris-HCl, pH 7.5, 0.1 % (v/v)Tween20, 5% (w/v) low fat milk powder) for 1h at 4°C. The petri dishes are washed three times with 2.5 ml PBS and 500 µl phage suspension containing 1×10^{11} (6 and 12mer libraries) or 7.5×10^8 TU (transforming units) is added and allowed to bind for 3h at 4°C. After washing ten times with 2.5ml TBST, bound phages are eluted with 400 µl elution buffer (0.1 N HCl-glycine pH2.2, 1mg/ml BSA) for 20 min. The eluates are neutralized with 24 µl 2M Tris base and used to infect 2.5ml log-phase E.coli K91 cells (50 min; 37°C). The whole suspension is transferred into 50ml Falcon tubes with 10 ml 2xYT medium containing 20 µg/ml tetracycline (2xYT, Tet) and incubated for 24 hours at 37°C with shaking. The cultures are spun to remove the bacteria and the phage particles are purified from the supernatant by PEG precipitation. The phage pellets are resuspended in 1 ml TBS and aliquots are used for a second round of biopanning which is carried out as for the first with the following modifications:

100 µl amplified phage (2×10^{11} TU) are reacted with GST-hdm2, MBP-hdm2 or DO-1 which has been absorbed in wells of a 96-well PVC assay plate at a concentration of 5 µg/ml. Amplified and purified phages from this round of biopanning are tested in an ELISA on the proteins used for their selection. For single clone screening E.coli K91 cells are infected with appropriate phage dilutions and spread on LB agar with 20 µg/ml tetracycline. Single colonies are transferred to wells of a 96-well tissue culture plate containing 200 µl 2xYT medium with 20 µg/ml tetracycline per well. Phage supernatant is collected for ELISA screening after a 24 hour incubation at 37°C with shaking. ELISA positive clones are grown up as 2 ml bacterial cultures in 2xYT medium with 20 µg/ml tetracycline for 24 hours. Phage are PEG precipitated and redissolved in 200 µl TBS buffer. Phage DNA is extracted with phenol/chloroform and ethanol precipitated. The DNA pellet is redissolved in 10 µl water and used as template for sequencing (Sequenase).

- 23 -

Phage Elisa

Solid phase hdm2

PVC assay plates are coated with 100 μ l antigen (GST-hdm2, MBP-hdm2, GST, MBP, or DO-1) at 5 μ g/ml in PBS overnight at 4°C and blocked with 200 μ l PBST-M (PBS, containing 5% (w/v) fat-free dried milk and 0.1% (v/v) Tween 20) for one hour at room temperature. 100 μ l phage suspension (supernatant or PEG concentrated phage) is diluted in PBST-M and added for three hours at 4°C. Bound phages are reacted with 100 μ l HRP-labelled sheep anti-M13 antibody (Pharmacia) for one hour at room temperature followed by substrate development with 100 μ l TMB/H₂O₂ (0.1 mg/ml TMB, 0.3% H₂O₂ in 0.1 M Na-acetate, pH 6.0) for 15 min. The reaction is stopped by adding 100 μ l 1M sulphuric acid to the substrate and the absorbance is measured at 450 nm. All washings between the incubation steps are done with tap water.

Solution phase hdm2

GST-, MBP-, TRX-hdm2 or baculovirus produced mdm2 (Sf9 cell extract) diluted in PBST-M are reacted in solution with hdm2- or GST-binding phage overnight at 4°C. Simultaneously, ELISA plates are coated with 100 μ l Rabbit anti-mouse antibodies (DAKO, Z0259) 1:1000 in 0.1 M NaHCO₃, pH 9.6. The plates are blocked as usual and incubated with monoclonal anti-mdm2 antibodies (hybridoma supernatant 1:5 diluted in PBST-M) for one hour. For the titration ELISA, purified SMP14 (8 μ g/ml in PBS) is used to coat the plate directly. In either case, the pre-incubated phage-hdm2 samples are transferred to the coated and blocked plate and incubated for two hours at room temperature. Bound phages are detected as described.

Results

Phage pools which have been recovered from two rounds of biopanning on solid phase GST- and MBP-hdm2 or DO-1 using samples of 6, 12, or 15mer phage display libraries are screened in ELISAs for antigen binding. Phage from 12 and 15mer libraries selected twice with GST-hdm2 or once with GST-hdm2 followed by MBP-hdm2 clearly bind to GST-hdm2, whereas the 6mer pool is completely negative. On the other hand, monoclonal anti-p53 antibody DO-1 is able to select phages from all three libraries proving the integrity of the 6mer library.

To determine whether phages specific for hdm2 are selected, the phage pools are tested against MBP-hdm2, GST and MBP. Both, 12 and 15mer pools contain hdm2 binding phages

- 24 -

(positive for MBP-hdm2, but negative for MBP alone). In addition, 15mer phages twice biopanned with GST-hdm2 (GST/GST-hdm2) are strongly selected for GST-binders. In the 15mer pool which is panned on MBP-hdm2 in the second round (GST/MBP-hdm2) the anti-GST signal is reduced, probably because GST is no longer present as a selecting antigen. GST does not pull out any phage from the 12mer library. Single phage clones are grown in 12 and 15mer pools and tested for GST, GST-hdm2 and MBP-hdm2 binding. Many clones are clearly positive with GST-hdm2 and MBP-hdm2. Phage clones from the 12 and 15mer pools which are shown to be positive with GST- and MBP-hdm2 are selected for further analysis. Phage DNA is extracted from each clone and the nucleotide inserts are sequenced. From 28 clones 6 unique insert sequences are obtained (amino acid sequences given in single letter code):

<u>mdm2 binding site on human p53</u>	<u>P L S Q E T F S D L W K L L P E N N V</u>
phage clone 12/1	M P R F M D Y W E G L N
phage clone 12/2	V Q N F I D Y W T Q Q F
phage clone 12/5	T G P A F T H Y W A T F
phage clone 15/1	I D R A P T F R D H W F A L V
phage clone 15/5	P R P A L V F A D Y W E T L Y
<u>phage clone BB3</u>	<u>P A F S R F W S D L S A G A H</u>
phage consensus	<u>P X F X D Y W X X L</u>

Aligning the corresponding amino acid sequences to each other reveals the phage consensus sequence P X F X D Y W X X L. It shows similarity to the known mdm2 binding motif on p53, T F S D L W (amino acid residues 18-23 of human p53; Picksley et al., Oncogene 9, 2523-2529 (1994)). All phage sequences contain the phenylalanine (F) and Tryptophan (W), and 4 out of 6 the aspartic acid (D) and leucine (L) found in the same position in the mdm2 motif. A strong selection for tyrosine (Y) and proline (P) in the phage sequences is not met by corresponding residues in the p53 sequence, although 2 successive prolines are found further upstream of the mdm2 binding site.

Further experiments are designed to evaluate the specificity of the hdm2-phage interaction and to prove that p53 and hdm2 phage bind to the same region on hdm2. For these experiment clones BB2/BB11 (GST binding control phage) and BB3/BB10 (hdm2 phage) are chosen. Phages are preincubated in solution with GST-hdm2, MBP-hdm2 or TRX-hdm2 and

- 25 -

the phage-hdm2 complexes are transferred to wells which contain different monoclonal anti-mdm2 antibodies bound to the solid phase via anti-mouse antibodies. Bound phages are detected. As expected, GST-phages are able to bind only to GST-hdm2. All three anti-mdm2 antibodies used (SMP14, 4B2, 3G5) are able to bind to hdm2 complexed with GST-phage. On the other hand, the hdm2-phage recognizes all three hdm2 fusion proteins including TRX-hdm2 never used for the phage selection (biopanning). The hdm2-phage complexes are efficiently pulled down by SMP14 and 4B2, but 3G5 is hardly able to bind to these complexes. It has been shown that mdm2-p53 complexes cannot be bound by 3G5, probably because the epitope of this antibody lies within the p53 binding domain of mdm2. Another experiment shows that hdm2-phages but not GST-phages are able to inhibit the interaction between hdm2 and TIP. TIP is thioredoxin with the mdm2 binding sequence of p53 inserted into its active site. In order to estimate the relative affinities of the different phage clones towards hdm2, a dilution series of GST-hdm2 is offered in solution to a fixed amount of phages. Phage-hdm2 complexes are pulled down by solid phase SMP14 and bound phages are detected. All phage clones tested show a very similar strong binding to GST-hdm2 with a half-maximal binding concentration of 0.5 to 10 nM GST-hdm2, dependent on the hdm2 preparation used. Experiments with baculovirus produced mdm2 (Sf9 cell extract) prove that the phage clones selected with hdm2 are able to bind to its mouse homologue as well. The phage sequences and a consensus sequence are produced as free peptides and tested for their relative capacity to block the interaction of MDM2 with p53 in three different ELISA formats. The new consensus sequence and some of the phage derived peptides show a remarkable increase in specific activity over the wild type p53 peptide sequence.

Materials and Methods for protein expression

1. Thioredoxin(Thio)-fusions

The clones are produced using the Invitrogen-Expression system. Using Bluescript containing the hdm2 gene as a template, PCR is carried out with the following primers (5'-3'):

START2 primer: gcg gat ccg atg gtg agg agc agg caa atg

STOP1 (to N221): gcc tgc agc cta att cga tgg cgt ccc tgt aga

STOP2 (full length): gc ctg cag cta ggg gaa ata agt tag cac aat

STOP3 (to D294): gc ctg cag cta atc ttc ttc aaa tga atc tgt

START3 primer (from D294): ggg gat cct gaa att tcc tta gct gac.

- 26 -

The resulting PCR products are cloned into pCR II (TA cloning kit, Invitrogen). The resulting plasmids are cleaved with BamH1 and PstI. The products are ligated into the BamH1/PstI cleaved pTrxFus. The plasmid is introduced into E.coli G1724. The following clones are obtained:

1. clone 1/8 Thio-MVRSRQ-M1...N221
2. clone 3/8 Thio-MVRSRQ-M1...D294
3. clone 2/7 Thio-MVRSRQ-M1...C478

2. Maltose binding protein (MBP)-fusion

The PCR product is obtained using the STOP1 primer described above with START1:

gc gga tcc atg gtg agg agc agg caa atg .

It is again cloned into pCR II. The plasmid is cut with BamH1 and PstI. The products are ligated into BamH1/PstI cleaved pMALc2 (New England Biolabs). The plasmids are then introduced into E.coli INV(F' cells (One ShotTMcompetent cell kit, Invitrogen).

Clone 4 (MBP-MVRSRQ-M1...N221) is obtained.

3. GST-fusion protein

A plasmid containing wild type hdm2 is used as a template in PCR. The primers are designed such that a BamH1 site is introduced into the 5' end and a EcoR1 site into the 3' end of the gene. The PCR products are digested and ligated into pGEX-2T (Pharmacia). The plasmid is then introduced into e.coli BL21 cells.

Protein expression:

1. Thioredoxin-fusion proteins

Cells are grown in RM medium (1xM9 salts, 2% Casamino acids, 1 % glycerol, 1mM MgCl₂, 100 g/ml ampicillin) overnight at 30°C. They are then inoculated into fresh Induction medium (1x M9 salts, 0.2 % Casamino acids, 0.5 % glucose, 1 mM MgCl₂, 100 g/ml ampicillin to a dilution of 1/20. Cells are then grown to an OD of 0.25 to 0.5 at 30°C. The culture is transferred to 37°C and induced with L-Tryptophan at a final concentration of 100 g/ml. After 3 h cells are harvested by centrifugation. The pellets are resuspended in ice cold 20 mM Tris/HCl, pH 8, 2.5 mM EDTA with protease inhibitors (1 mM PMSF, 1 mM benzamidine, leupeptin, aproitin and pepstatin at 10 g/ml each. The cells are lysed by sonication, shock

- 27 -

freezing, quick thawing. The cycle is repeated two more times. The lysate is then centrifuged at 4000 rpm for 15 min at 4°C. The supernatant is used.

2. Maltose binding protein-fusions

Cells are grown in rich Medium with glucose and ampicillin (10 g tryptone, 5 g yeast extract, 5 g NaCl, 2 g glucose and 100 g/ml ampicillin to an OD of 0.5. They are then induced with IPTG at a final concentration of 0.3 mM. Incubation is continued at 37°C for another 2 h. Cells are harvested by centrifugation and resuspended in column buffer (1/20th of original volume, 20 mM Tris-HCl, pH 7.4; 200 mM NaCl; 1 mM EDTA; 1 mM DTT plus protease inhibitors as mentioned above. Cells are frozen over night at -20°C. They are thawed in cold water, sonicated on ice in short pulses of 6 x 10 seconds and spun at 9000 rpm for 30 min at 4°C. The supernatant is diluted 1/5 with column buffer and loaded on an amylose resin (New England Biolabs, 15 ml, prepared in column buffer). Elution is carried out with column buffer + 10 mM Maltose. Active fractions are pooled, concentrated and desalted on a 10 DG column (BioRad). They are stored in 50 mM Tris /Hcl pH 7.4, 50 mM NaCl, 20 % glycerol, 1 mM DTT.

3. GST-hdm2 (1-188)

Bacteria cultures are grown to OD 0.8. They are cooled to RT and induced with 1 mM IPTG, then grown for 4h at 27°C. Cells are harvested and pellets flash frozen in liquid nitrogen. Pellets are resuspended in ice cold buffer A (0.5 M NaCl, 2.7 mM KCl, 10 mM Na₂HPO₄, 1.8 mM KH₂PO₄, 1 mM PMSF, 1 mM EDTA, 10 mM 2-mercaptoethanol, pH 7.3). They are lysed by a French press or alternatively by sonication. After centrifugation the soluble fraction is loaded onto a glutathione sepharose 4B column (Pharmacia) equilibrated with buffer A. The protein is then eluted with buffer B (50 mM Tris/HCl, 10 mM reduced glutathione, 0.5 M NaCl, 1 mM EDTA, 1 mM PMSF or benzamidine, 10 mM 2-mercaptoethanol or 1 mM DTT, pH 8.0.) Active fractions are desalted on Sephadex G25 or 10 DG (BioRad) preequilibrated with buffer C (50 mM Tris/HCl, 50 mM NaCl, 20 % glycerol, 10 mM 2-mercaptoethanol or 1 mM DTT, 0.1 % Triton x-100, pH 7.6). The protein is used for Elisas or further purified on a Mono Q column (Pharmacia) preequilibrated with buffer C. The protein is eluted with a linear gradient of buffer C containing 1 M NaCl. The fractions containing fusionprotein are pooled, concentrated (Centricon 30), flash frozen in liquid nitrogen and stored at - 70 (C.

- 28 -

ELISAs

Three different Elisas are employed to analyse the interaction between hdm2 and p53. They are named according to the reagent which is used to coat the Elisa plates. All Elisas are carried out at 4°C.

1. Elisa P2

P2 is a biotinylated peptide consisting of 18 amino acids of the Nterminal part of p53, namely:

Biotin-S-G-S-G-E-P-P-L-S-Q-E-T-F-S-D-L-W-K-L-L-P-E

Plates are incubated overnight with 10 µg/ml streptavidin at 37°C. They are blocked with 2% BSA in PBS for 1 h. Peptide is applied at 5 µg/ml in blocking solution for 1 h. A second blocking step is carried out with 5 % milk, 0.1 % Tween20 in PBS (blocking solution2) for a minimum of 10 min. Hdm2fusionproteins are diluted in blocking solution2 and applied for 1h. Bound hdm2 is detected with SMP 14 hybridoma cell supernatant diluted 1/2 in block solution2. HRP-anti-mouse IgG (DAKO) is used as second antibody. Washing between incubations is carried out 6 times with tap water.

2. Elisa TIP

TIP is thioredoxin which has additional amino acids inserted into its active site. These are derived from the N-terminus of p53 and are the following:

P-P-L-S-Q-E-T-F-S-D-L-W-K-L-L-P-E-N.

The following oligonucleotides are used

P1: 5' gt ccg cct ctg agt cag gaa aca ttt tca gac cta tgg aaa cta ctt cct gaa aac g 3'

P2: 5' g acc gtt ttc agg aag tag ttt cca tag gtc tga aaa atg ttt cct gac tca gag gcg 3'

10 ng of each P1 and P2 are phosphorylated using PNK and annealed for 1 h at 37°C. The vector pTRX (InVitrogen) is cleaved with RsrII and dephosphorylated. After ligation the plasmids are introduced into E.coli 1724 cells.

Plasmid containing bacteria are grown in RM medium at 30°C and induced with L-Trp as described earlier. A soluble lysate is made by freeze -thaw-sonication cycles. This lysate is then heat shocked at 80°C for 10 min. The soluble fraction is used to coat Elisa-plates at a concentration of 40 µg/ml in PBS o/n..Plates are blocked in blocking solution2 for 1 h.

Incubation with hdm2 fusionproteins and detection is carried out as described for Elisa P2.

- 29 -

3. Elisa hdm2

Plates are coated with 2.6 µg/ml GST-hdm2(1-188) in PBS at 4°C o/n. They are blocked in blocking solution 2 for 1 h. Full length p53, lysozyme lysate from *E. coli*, purified on heparin-sepharose is applied in blocking solution 2 with 10 % glycerol and 10 mM DTT for 1h. Binding is established with mAb 421 and HRP coupled anti mouse IgG.

HRP activity is measured using TMB. For inhibition Elisas inhibitors are preincubated with either hdm2-fusionproteins or p53 for 15 min before the mixture is transferred to the plate. Peptide inhibitors are dissolved in DMSO.

Example 8: Purification of p53 D30

The human wild type p53 gene is used as a template for PCR to obtain the gene fragment encoding for residues 1 to 362 of the 393 amino acids of natural (human) p53 (p53D30). The oligonucleotides used for PCR are designed such that a NdeI restriction site is introduced at the 5' end and a BamHI site at the 3' end. The PCR fragments digested by NdeI and BamHI are ligated with a NdeI/ BamHI cleaved pET-3a plasmid. The complete gene is sequenced and the expression plasmid is introduced into *E. coli* strain BL21(DE3)pLysS (Novagen).

For protein expression bacteria cultures are inoculated by a 100-fold diluted overnight culture and grown in Luria Broth medium in the presence of 100 µg ampicillin/ ml at 37 °C to OD₆₀₀ = 0.8. The cultures are then cooled on ice to room temperature, induced with 1 mM Isopropyl-D-thiogalactopyranoside and grown for four additional hours at 27°C. The cells are then harvested by centrifugation and the pellets flash frozen in liquid nitrogen and stored at -70 °C.

The cell pellets containing the p53D30 protein are resuspended in ice cold buffer D (50 mM 4-(2-hydroxyethyl)-piperazine-ethane-sulfonic acid (Hepes.NaOH), 10 % (v/v) glycerol, 0.1 mM EDTA, 0.1 % (v/v) Triton X-100, 5 mM 1,4-dithio-DL-threitol (DTT), 1 mM PMSF - pH = 7.6) and lysed with a French press at 1000 psi. After centrifugation, the soluble fraction is loaded onto a HiTrap Heparin column (Pharmacia Biotech) preequilibrated at 4 °C with buffer D. The column is first washed with buffer D containing 22 % buffer E (50 mM Hepes.NaOH, 1 M KCl, 10 % (v/v) glycerol - pH = 7.6) and p53D30 is eluted with a linear gradient to 100 % buffer E. The fractions containing p53D30 are pooled and loaded onto a HiTrap metal chelation column (Pharmacia

- 30 -

Biotech) charged with nickel and preequilibrated at 4 °C with buffer F (50mM Hepes.NaOH, 0.5 M KCl, 10 % (v/v) glycerol - pH = 7.6). After washing the column with buffer F containing 20 % buffer G (50 mM Hepes.NaOH, 0.5 M KCl, 10 % (v/v) glycerol, 0.1 M Imidazole - pH = 7.6), p53D30 is eluted with 45 % buffer G. 50 mM 2-mercaptoethanol and 1 mM ZnCl₂ are added to the solution and the protein is dialysed at 4 °C against 50 mM Hepes.NaOH, 0.5 M KCl, 20 % (v/v) glycerol, 50 mM 2-mercaptoethanol, 1 mM ZnCl₂ - pH = 7.6. p53D30 is concentrated to 1 mg/ml (Amicon 30 kDa cut off membrane), flash frozen in liquid nitrogen and stored at -70°C.

Protein analysis

The purity of the protein preparation is evaluated by gel scanning (Schimadzu CS-930) on a SDS-PAGE (Laemmli, U.K. (1970) Nature, 227, 680-385) stained with Coomassie blue. Protein concentration is determined according to Bradford, M.B. (1976) Anal. Biochem., 72, 248-254).

- 31 -

Claims

1. A peptide, or a derivative thereof, capable of binding to MDM2, particularly human DM2, and specifically inhibiting or blocking the binding of MDM2 to the p53 protein, particularly human p53, *in vitro* or *in vivo*.
2. A peptide according to claim 1 which comprises an amino acid motif of the formula
$$R_1-X-F-X-R_2-R_3-W-X-X-R_4 \quad (I),$$
wherein
 R_1 and is a proline (P), leucine (L), glutamic acid (E), cysteine (C) or glutamine (Q),
X stands for one (any) natural amino acid,
 R_3 is histidine (H), phenylalanine (F) or tyrosine (Y),
 R_4 is phenylalanine (F), glutamine (Q) or leucine (L); and
F is phenylalanine and W is tryptophan;
or a derivative thereof.
3. A peptide according to claim 2 comprising the amino acid motif of formula (I) consisting of no more than fifteen amino acids (15mers), or a derivative thereof.
4. A peptide according to claim 2 selected from the group consisting of the peptides with the sequences M-P-R-F-M-D-Y-W-E-G-L-N, Q-P-T-F-S-D-Y-W-K-L-L-P, and P-X-F-X-D-Y-W-X-X-L, or a derivative thereof.
5. A derivative of a peptide according to claim 2 which is a fragment comprising at least eight consecutive amino acids of the sequence of formula (I), or a derivative thereof.
6. A fragment according to claim 5 selected from the group of fragments consisting of:
P-A-F-T-H-Y-W-P, P-T-F-S-D-Y-W-P and P-R-F-M-D-Y-W-P, or a derivative thereof.
7. Use of a peptide or derivative according to claim 1 for the identification of a molecule binding to MDM2.

- 32 -

8. Use of a peptide or derivative according to claim 1 for the purification of a binding partner, particularly MDM2.

9. Use of a peptide or derivative according to claim 1 in a method aiming at identifying or designing compounds which interfere with the binding of MDM2 to p53.

10. Use of a peptide or derivative according to claim 1 for diagnosis of a disease.

11. A pharmaceutical composition that is suitable for administration to a warm-blooded animal or to cells or cell lines derivable from a warm-blooded animal for the treatment or prevention of a disease that responds to inhibition of the interaction of p53 with MDM2, said composition comprising an amount of a peptide or a derivative thereof according to claim 1, which is effective for said inhibition, together with at least one pharmaceutically acceptable carrier.

12. The use of a peptide or derivative according to claim 1 for the preparation of a pharmaceutical composition for the treatment or prevention of a disease that responds to inhibition of the interaction of p53 with MDM2.

13. A process for the preparation of a peptide or a derivative thereof according to claim 1 comprising reacting a fragment of such peptide, which has a free carboxy group, or a reactive derivative thereof, with a complementary fragment that has an amino group with at least one free hydrogen atom, or with a reactive derivative thereof, resulting in the formation of a peptide bond, and, if desired, removing a present protecting group, or derivatising said peptide or derivative.

- 33 -

Abstract

The present invention relates to compounds capable of binding to the oncogene protein MDM2, processes for the preparation of such compounds, pharmaceutical preparations comprising such compounds, and uses of said compounds, e.g. in the therapeutic (including prophylactic) treatment of an animal or especially of the human body.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.